ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi plans to spend $550 million on a vaccine-manufacturing facility in Neuville-sur-Saône, France, a 5-year project expected to create 200 full-time jobs. Sanofi will also invest $135 million in an R&D facility in Marcy-l’Étoile. Geared toward meeting production needs in any future pandemics, the plant will feature a central unit housing several modules that can make 3–4 vaccines simultaneously. Sanofi and GlaxoSmithKline announced in April that they are collaborating on the development of an adjuvanted COVID-19 vaccine, for which the French firm will contribute an antigen based on recombinant DNA technology.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter